Experiences with next-generation sequencing in relapsed acute myeloid leukemia: a patient case series

Main Article Content

Dr. Johanna Flach
Dr. Evgenii Shumilov
Dr. Naomi Porret
Inna Shakhanova
Myriam Legros
Dr. Marie-Noëlle Kronig
Dr. Raphael Joncourt
Prof. Ulrike Bacher
Prof. Thomas Pabst
(*) Corresponding Author:

Abstract

Not applicable


Downloads month by month

Downloads

Download data is not yet available.

Article Details

Author Biographies

Dr. Johanna Flach, Medical Faculty Mannheim of the Heidelberg University, Mannheim

Department of Hematology and Oncology

Dr. Evgenii Shumilov, University Medicine Göttingen (UMG), Göttingen

Department of Hematology and Medical Oncology

Dr. Naomi Porret, Inselspital, Bern University Hospital, Bern

University Department of Hematology and Central Hematology Laboratory; Center of Laboratory Medicine (ZLM)/University Institute of Clinical Chemistry

Inna Shakhanova, University Medicine Göttingen (UMG), Göttingen

Department of Nephrology and Rheumatology

Myriam Legros, Inselspital, Bern University Hospital, Bern

Center of Laboratory Medicine (ZLM)/University Institute of Clinical Chemistry

Dr. Marie-Noëlle Kronig, Inselspital, Bern University Hospital, Bern

Department of Medical Oncology

Dr. Raphael Joncourt, Inselspital, Bern University Hospital, Bern

University Department of Hematology and Central Hematology Laboratory; Center of Laboratory Medicine (ZLM)/University Institute of Clinical Chemistry

Prof. Ulrike Bacher, Inselspital, Bern University Hospital, Bern

University Department of Hematology and Central Hematology Laboratory; Center of Laboratory Medicine (ZLM)/University Institute of Clinical Chemistry

Prof. Thomas Pabst, Inselspital, Bern University Hospital, Bern

Department of Medical Oncology

References

1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391-2405.
2. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129:424-447.
3. Burnett AK, Goldstone A, Hills RK, et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol 2013;31:1293-1301.
4. Greif PA, Hartmann L, Vosberg S, et al. Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients. Clin Cancer Res 2018;24:1716-1726.
5. Quek L, Ferguson P, Metzner M, et al. Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. Blood Adv 2016;1:193-204.
6. Wong TN, Ramsingh G, Young AL, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 2015;518:552-555.
7. Flach J, Shumilov E., Wiedemann, G., et al. Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia. Hematol Oncol 2020;1-7.
8. Shumilov E, Flach J, Joncourt R, et al. Clinical value of molecular MRD monitoring by next-generation sequencing in patients with IDH2 mutated AML. Leuk Lymphoma 2019;60:2588-2590.
9. Bacher U, Porret N, Joncourt R, et al. Pitfalls in the molecular follow up of NPM1 mutant acute myeloid leukemia. Haematologica 2018;103:e486-e488.
10. McCormick SR, McCormick MJ, Grutkoski PS, et al. FLT3 mutations at diagnosis and relapse in acute myeloid leukemia: cytogenetic and pathologic correlations, including cuplike blast morphology. Arch Pathol Lab Med 2010;134:1143-1151.
11. Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med 2019;381:1728-1740.
12. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med 2017;377:454-464.
13. Norsworthy KJ, Luo L, Hsu V, et al. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation. Clin Cancer Res 2019;25:3205-3209.
14. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 2017;130:722-731.